QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

Thorax

Volumn 65, Issue 12, 2010, Pages 1086-1091

  Van Noord, Jan A ^a   Buhl, Roland ^b   LaForce, Craig ^c   Martin, Carmen ^d   Jones, Francis ^d   Dolker, Michael ^e   Overend, Tim ^d  

^a Sittard Geleen Heerlen   (Netherlands)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c North Carolina Clinical Research   (United States)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; INDACATEROL; PLACEBO; QVA 149; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

EID: 78649635656     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.139113     Document Type: Article

References (28)

1. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.com/ (accessed 2009).
2. Cazzola M, Matera MG. The effective treatment of COPD: anticholinergics and what else? Drug Discov Today Ther Strateg 2006;3:277-86.
3. Cazzola M, Santus P, Verga M, et al. The functional impact of adding salmeterol to tiotropium in patients with stable COPD. Respir Med 2004;98:1214-21.
4. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125:249-59.
5. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006;73:414-19.
6. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005a;26:214-22.
7. van Noord J, Aumann L, Janssens E, et al. Combination therapy of tiotropium plus salmeterol superior to single agent therapy in terms of dyspnea improvement in COPD (Abstract). Chest 2005b;128:177S.
8. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-17.
9. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134:255-62.
10. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511-20.
11. 1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD (Abstract). Chest 2005;128:258s.
12. Cazzola M, Noschese P, Salzillo A, et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005;99:524-8.
13. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102:479-87.
14. Tashkin D, Pearle J, Iezzoni D, et al. Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: findings from a randomized, placebo-controlled trial. J COPD 2009a;6:17-25.
15. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85.
16. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001;119:1347-56.
17. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily b2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-9.
18. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010;23:438-44.
19. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44.
20. Verkindre C, Fukuchi Y, Flémale A, et al. Sustained 24-h efficacy of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:1482-9.
21. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
22. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
23. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11.
24. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-68.
25. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009b;103:516-24.
26. Claxton AJ, Cramer J, Pierce CA. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
27. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002;109(Suppl 6):S554-9.
28. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007;101:1895-902.